Guangdong Taienkang Pharmaceutical Co., Ltd.

SZSE:301263 Voorraadrapport

Marktkapitalisatie: CN¥6.2b

Guangdong Taienkang Pharmaceutical Toekomstige groei

Future criteriumcontroles 5/6

Guangdong Taienkang Pharmaceutical is forecast to grow earnings and revenue by 37.7% and 24.5% per annum respectively. EPS is expected to grow by 37.4% per annum. Return on equity is forecast to be 18.2% in 3 years.

Belangrijke informatie

37.7%

Groei van de winst

37.4%

Groei van de winst per aandeel

Pharmaceuticals winstgroei19.3%
Inkomstengroei24.5%
Toekomstig rendement op eigen vermogen18.2%
Dekking van analisten

Low

Laatst bijgewerkt16 Sep 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Weak Statutory Earnings May Not Tell The Whole Story For Guangdong Taienkang Pharmaceutical (SZSE:301263)

Sep 03
Weak Statutory Earnings May Not Tell The Whole Story For Guangdong Taienkang Pharmaceutical (SZSE:301263)

Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) P/E Still Appears To Be Reasonable

Aug 23
Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) P/E Still Appears To Be Reasonable

Here's Why Guangdong Taienkang Pharmaceutical (SZSE:301263) Can Manage Its Debt Responsibly

Jul 22
Here's Why Guangdong Taienkang Pharmaceutical (SZSE:301263) Can Manage Its Debt Responsibly

Guangdong Taienkang Pharmaceutical (SZSE:301263) Is Paying Out Less In Dividends Than Last Year

May 22
Guangdong Taienkang Pharmaceutical (SZSE:301263) Is Paying Out Less In Dividends Than Last Year

Guangdong Taienkang Pharmaceutical (SZSE:301263) Seems To Use Debt Quite Sensibly

Feb 26
Guangdong Taienkang Pharmaceutical (SZSE:301263) Seems To Use Debt Quite Sensibly

Winst- en omzetgroeiprognoses

SZSE:301263 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20261,362378N/A3362
12/31/20251,121296N/A2682
12/31/2024914223N/A1672
9/30/2024752135-14928N/A
6/30/2024751137-15348N/A
3/31/2024756154-19117N/A
12/31/2023761160-10694N/A
9/30/20237911897102N/A
6/30/202381420646155N/A
3/31/202379417345148N/A
1/1/202378317559149N/A
9/30/202275916876160N/A
6/30/202271214049112N/A
3/31/202269715793142N/A
1/1/202265412075120N/A
9/30/202166112446113N/A
6/30/202166812753123N/A
3/31/202167013338121N/A
12/31/202070916132126N/A
9/30/202066213856116N/A
6/30/202061211979120N/A
3/31/20205658795118N/A
12/31/2019496556775N/A
9/30/2019496564256N/A
6/30/2019512694062N/A
3/31/2019523764473N/A
12/31/2018514743969N/A
9/30/2018486711351N/A
6/30/201848067N/A44N/A
3/31/201845758N/A27N/A
12/31/201745055N/A23N/A
9/30/201743043N/A27N/A
6/30/201740835N/A21N/A
3/31/201737831N/A-10N/A
12/31/201636728N/A2N/A
9/30/201638238N/A10N/A
6/30/201639849N/A19N/A
3/31/201638445N/A17N/A
12/31/201537042N/A16N/A
9/30/201533736N/AN/AN/A
6/30/201530429N/A7N/A
3/31/201530535N/A28N/A
12/31/201430440N/A25N/A
12/31/201328048N/A19N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: 301263's forecast earnings growth (37.7% per year) is above the savings rate (2.9%).

Winst versus markt: 301263's earnings (37.7% per year) are forecast to grow faster than the CN market (25.8% per year).

Hoge groeiwinsten: 301263's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: 301263's revenue (24.5% per year) is forecast to grow faster than the CN market (14% per year).

Hoge groei-inkomsten: 301263's revenue (24.5% per year) is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: 301263's Return on Equity is forecast to be low in 3 years time (18.2%).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y